Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
Stopped Company decision to discontinue the AVE1642 development program, not due to any safety or efficacy concerns
Conditions
Interventions
- DRUG: AVE1642
- DRUG: sorafenib
- DRUG: erlotinib
Sponsor
Sanofi